156 related articles for article (PubMed ID: 28767454)
21. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor.
Sheu J; Hawryluk EB; Litsas G; Thakuria M; LeBoeuf NR
Clin Breast Cancer; 2015 Feb; 15(1):e77-81. PubMed ID: 25445421
[No Abstract] [Full Text] [Related]
22. FDA Approval Summary: Ramucirumab for Gastric Cancer.
Casak SJ; Fashoyin-Aje I; Lemery SJ; Zhang L; Jin R; Li H; Zhao L; Zhao H; Zhang H; Chen H; He K; Dougherty M; Novak R; Kennett S; Khasar S; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2015 Aug; 21(15):3372-6. PubMed ID: 26048277
[TBL] [Abstract][Full Text] [Related]
23. Infliximab-induced acne: a new case and review of published reports.
Steels E; Peretz A; Vereecken P
J Dermatolog Treat; 2009; 20(1):59-60. PubMed ID: 18608731
[No Abstract] [Full Text] [Related]
24. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
26. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; Sanmartín O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
[TBL] [Abstract][Full Text] [Related]
28. Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma.
Hsiao YW; Lin YC; Hui RC; Yang CH
J Clin Oncol; 2011 Apr; 29(12):e340-1. PubMed ID: 21263088
[No Abstract] [Full Text] [Related]
29. Eruptive cherry angiomas developing in a patient treated with ramucirumab.
Espinosa Lara P; Medina-Puente C; Riquelme Oliveira A; Jiménez-Reyes J
Acta Oncol; 2018 May; 57(5):709-711. PubMed ID: 29188737
[No Abstract] [Full Text] [Related]
30. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
[TBL] [Abstract][Full Text] [Related]
31. Acneiform eruptions.
Dessinioti C; Antoniou C; Katsambas A
Clin Dermatol; 2014; 32(1):24-34. PubMed ID: 24314375
[TBL] [Abstract][Full Text] [Related]
32. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas.
Ueda S; Satoh T; Gotoh M; Gao L; Doi T
Oncologist; 2015 May; 20(5):493-4. PubMed ID: 25888272
[TBL] [Abstract][Full Text] [Related]
33. The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis.
Balagula Y; Wu S; Su X; Lacouture ME
Ann Oncol; 2011 Nov; 22(11):2366-2374. PubMed ID: 21402620
[TBL] [Abstract][Full Text] [Related]
34. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity.
Safran H; Suntharalingam M; Dipetrillo T; Ng T; Doyle LA; Krasna M; Plette A; Evans D; Wanebo H; Akerman P; Spector J; Kennedy N; Kennedy T
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):391-5. PubMed ID: 17980508
[TBL] [Abstract][Full Text] [Related]
35. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
36. Dermatological adverse reactions to cancer chemotherapy.
Pavey RA; Kambil SM; Bhat RM
Indian J Dermatol Venereol Leprol; 2015; 81(4):434. PubMed ID: 26144855
[No Abstract] [Full Text] [Related]
37. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer.
Gholam D; Chebib A; Hauteville D; Bralet MP; Jasmin C
Anticancer Drugs; 2007 Aug; 18(7):835-7. PubMed ID: 17581308
[TBL] [Abstract][Full Text] [Related]
38. Acneiform eruption and pruritus in a patient with quetiapine therapy.
Kansal NK; Sharma M
Skinmed; 2013; 11(5):317-8. PubMed ID: 24340477
[No Abstract] [Full Text] [Related]
39. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
40. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
